SA
DSGN icon

SpiderRock Advisors’s Design Therapeutics DSGN Stock Holding History

SpiderRock Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$145K Buy
+26,965
New +$127K ﹤0.01% 808

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SpiderRock Advisors's DSGN Position: Q3 2024 in Review

SpiderRock Advisors opened a new position in Design Therapeutics (DSGN) in Q3 2024: 26,965 shares worth $145K. The stake represents ﹤0.01% of the portfolio and ranks #808 among its holdings.

100 funds tracked by Wall St. Rank hold DSGN as of Q3 2024.

  • SpiderRock Advisors held 26,965 shares of Design Therapeutics worth $145K as of Q3 2024.
  • Design Therapeutics was a new SpiderRock Advisors position in Q3 2024.
  • Design Therapeutics made up ﹤0.01% of SpiderRock Advisors's portfolio in Q3 2024, its #808 holding.
  • 100 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.